BCM
NVO

Blume Capital Management’s Novo Nordisk NVO Stock Holding History

Blume Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9K Hold
437
– – ﹤0.01% 256
2026
Q1 		$16.1K Buy
437
+362
+483% +$17.2K ﹤0.01% 254
2025
Q4 		$3.82K Hold
75
– – ﹤0.01% 292
2025
Q3 		$4.16K Sell
75
-145
-66% -$8.49K ﹤0.01% 308
2025
Q2 		$15.2K Buy
220
+56
+34% +$3.81K ﹤0.01% 257
2025
Q1 		$11.4K Buy
164
+89
+119% +$7.35K ﹤0.01% 261
2024
Q4 		$6.45K Sell
75
-51
-40% -$5.51K ﹤0.01% 279
2024
Q3 		$15K Buy
126
+26
+26% +$3.47K ﹤0.01% 252
2024
Q2 		$14.3K Sell
100
-35
-26% -$4.64K ﹤0.01% 235
2024
Q1 		$17.3K Sell
135
-65
-33% -$7.74K ﹤0.01% 223
2023
Q4 		$20.7K Hold
200
– – 0.01% 216
2023
Q3 		$18.2K Hold
200
– – 0.01% 218
2023
Q2 		$16.2K Buy
+200
New +$16.3K ﹤0.01% 224
2016
Q4 		– Sell
-458
Closed -$10K – 207
2016
Q3 		$10K Hold
458
– – 0.01% 154
2016
Q2 		$12K Buy
+458
New +$12.6K 0.01% 165

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Blume Capital Management's NVO Position: Q2 2026 in Review

Blume Capital Management held its Novo Nordisk (NVO) position steady in Q2 2026 at 437 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #256.

Blume Capital Management first reported a position in NVO in Q2 2016 and has held it in 15 quarters since. 580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Blume Capital Management held 437 shares of Novo Nordisk worth $20.9K as of Q2 2026.
  • Blume Capital Management left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of Blume Capital Management's portfolio in Q2 2026, its #256 holding.
  • Blume Capital Management first reported a position in Novo Nordisk in Q2 2016 and has held it in 15 quarters since.
  • 580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Blume Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.